Precigen

Q: What industry does Precigen belong to?

Precigen is in the industry of: Business Services General , Business Services

Q: What is Precigen competition?

Precigen top competitors include: Poseida Therapeutics , Agenus Inc , Biocytogen LLC , Personalis

Business Services · Maryland, United States · 456 Employees

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases. The company was founded in 1998 and is headquartered in Germantown, Maryland.Read More

Contact

Who is Precigen

Headquarters

20358 Seneca Meadows Pkwy, Germantown, Maryland, 20876, United States

Phone Number

(301) 556-9900

Website

www.precigen.com

Revenue

$111.4M

Stock Symbol

PGEN

Industry

Business Services General

Business Services

Is this data correct?

View contact profiles from Precigen

Top Competitors of Precigen

Poseida Therapeutics
283
$32.7M
1
Agenus Inc
441
$309.9M
2
Biocytogen LLC
1,300
$274.7M
3
Personalis
325
$68.7M
4
Turning Point Therapeutics Inc
248
$15.5M
5
Fate Therapeutics Inc
511
$63.1M
6

Precigen Org Chart

Helen "Sabzevari

President & Chief Executive ...

Phone

Christopher Rogers

Chief Executive Officer, Pre...

Phone

Rutul Shah

Chief Operating Officer

Phone

View Email Formats for Precigen

Precigen Company Metrics

Company Insights

Employee Growth Rate

Funding

Funding DateJan 26, 2021

RoundStock Issuance/Offering

Amount$129.4M

Investors

$129.4M

Total Funding Amount

$129.4M

Most Recent Funding Amount

Number of Funding Rounds

Acquisitions & Subsidiaries

Nov 21, 2009

GT Life Sciences

Medistem

Agarigen

Oxitec

Intrexon Actobiotics

GenVec

See More Acquisitions & Subsidiaries

Precigen Tech Stack

CKEditor

Dokeos

DOKEOS

Gupy

Kallidus

See more technologies

Precigen News & Media

Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumors
– Milestone represents the first patient dosed with the next generation UltraCAR-T, incorporating PD-1 checkpoint inhibition in addition to three effector genes – – Proprietary technology for checkpoint blockade intrinsic to UltraCAR-T cells avoids the need for combination with a systemic...
Mar 29, 2023
www.prnewswire.com
Insiders who bought Precigen, Inc. (NASDAQ:PGEN) stock in the last 12 months recover some losses, but still down US$62k
Insiders who bought US$207k worth of Precigen, Inc. ( NASDAQ:PGEN ) stock in the last year recovered part of their...
Mar 9, 2023
news.yahoo.com
Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
– Achieved significant clinical progress for UltraCAR-T® and AdenoVerse™ investigational therapeutics in 2022 – – Presented positive clinical data for PRGN-2012 AdenoVerse immunotherapy in recurrent respiratory papillomatosis (RRP) showing favorable safety profile and significant...
Mar 6, 2023
www.prnewswire.com
Precigen Announces Closing of Public Offering of Common Stock
Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold 42,857,143 shares of its common stock at a public offering price of $1.75 per share. Gross proceeds to Precigen from the offering were approximately $75.0 million before deducting the underwriting discount and other offering expenses payable by Precigen.
Jan 27, 2023
finance.yahoo.com
Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock
GERMANTOWN, Md., Jan. 24, 2023 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offering price of $1.75 per share. Precigen has also granted the underwriters a 30-day option to...
Jan 25, 2023
www.prnewswire.com